drugset / Trial / NCT02024555
Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
Phase 2
Completed
97 enrolled
Vanderbilt University
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of this study is to investigate the efficacy and safety of oral antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis. We suspect that the CLEAR regimen will improve the absolute FVC percent predicted in chronic pulmonary sarcoidosis participants.
Timeline
- Start
- 2014-03
- Primary completion
- 2019-04-01
- Completion
- 2019-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Azithromycin | Small molecule | 250 mg | Oral |
| Comparator | Ethambutol | Small molecule | 1200 mg | Oral |
| Comparator | Levofloxacin | Small molecule | 500 mg | Oral |
| Comparator | Rifampin | Small molecule | 600 mg | Oral |